PTGX Protagonist Therapeutics Inc

$84.61

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/17/2025

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.

Website: https://www.protagonist-inc.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1377121
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, US
Valuation
Market Cap
$2.84B
P/E Ratio
10.94
PEG Ratio
0.00
Price to Book
4.21
Performance
EPS
$4.23
Dividend Yield
—
Profit Margin
63.30%
ROE
54.40%
Technicals
50D MA
$44.51
200D MA
$42.18
52W High
$60.60
52W Low
$24.22
Fundamentals
Shares Outstanding
61M
Target Price
$69.10
Beta
2.29

PTGX EPS Estimates vs Actual

● Estimated
● Actual

PTGX News & Sentiment

Nov 06, 2025 • Zacks Commentary NEUTRAL
Protagonist Therapeutics ( PTGX ) Reports Q3 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -5.08% and -52.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 04, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Bolt Biotherapeutics, Inc. ( BOLT ) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nov 04, 2025 • Zacks Commentary NEUTRAL
Kymera Therapeutics, Inc. ( KYMR ) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Protagonist Therapeutics ( PTGX ) Expected to Beat Earnings Estimates: Should You Buy?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 28, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Regeneron ( REGN ) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 20, 2025 • Motley Fool SOMEWHAT-BULLISH
2 Top Dividend Kings Every Income Investor Should Own
These companies pay durable and steadily rising dividends.
Sentiment Snapshot

Average Sentiment Score:

0.163
50 articles with scored sentiment

Overall Sentiment:

Bullish

PTGX Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.55
  • Estimate: $-0.58
  • Whisper: —
  • Surprise %: 5.2%
May 06, 2025
Mar 31, 2025 (Post market)
-0.3 Surprise
  • Reported EPS: $-0.19
  • Estimate: $0.11
  • Whisper: —
  • Surprise %: -272.7%
Feb 21, 2025
Dec 31, 2024 (Post market)
1.73 Surprise
  • Reported EPS: $1.98
  • Estimate: $0.25
  • Whisper: —
  • Surprise %: 692.0%
Nov 07, 2024
Sep 30, 2024 (Post market)
0.06 Surprise
  • Reported EPS: $-0.54
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: 10.0%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.1 Surprise
  • Reported EPS: $-0.50
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: 16.7%
May 07, 2024
Mar 31, 2024 (Post market)
2.07 Surprise
  • Reported EPS: $3.26
  • Estimate: $1.19
  • Whisper: —
  • Surprise %: 173.9%
Feb 27, 2024
Dec 31, 2023 (Post market)
0.47 Surprise
  • Reported EPS: $0.44
  • Estimate: $-0.03
  • Whisper: —
  • Surprise %: 1566.7%
Nov 02, 2023
Sep 30, 2023 (Post market)
0.11 Surprise
  • Reported EPS: $-0.58
  • Estimate: $-0.69
  • Whisper: —
  • Surprise %: 15.9%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.03 Surprise
  • Reported EPS: $-0.68
  • Estimate: $-0.65
  • Whisper: —
  • Surprise %: -4.6%

Financials